Over the past few years, considerable progress has been made in understanding the biology, pharmacology and structure of muscarinic acetylcholine receptors (mAChRs). Here, Wess and colleagues discuss the therapeutic potential of targeting this class of receptors in a range of diseases, including Alzheimer's disease and type 2 diabetes, and consider novel aspects of mAChR pharmacology that could enable modulation of specific receptor subtypes.
- Andrew C. Kruse
- Brian K. Kobilka
- Jürgen Wess
